<DOC>
	<DOCNO>NCT02408991</DOCNO>
	<brief_summary>The purpose study measure concentration cell proteins patient 's blood administration Nuopogen ( Filgrastim ) , medication FDA approve stem cell mobilization , combination program pneumatic compression device ( PPCD ) ( Art-Assist Device ) . The Art-Assist Device FDA approve device promotes blood flow patient 's leg . A patient prescribed device drug help improve poor circulation his/her leg . The use Nuopogen along Art-Assist Device approve FDA consider experimental . This study design find well Art-Assist Device work , well drug work mobilize stem cell . Instead , study well cell line blood vessel calf respond increase shear stress , well increase population certain cell blood stream effect new blood vessel form . It important clinical reason , purpose study , patient use Art-Assist Device prescribe daily basis discuss patient 's doctor</brief_summary>
	<brief_title>Use Art-assist Neupogen Treat Chronic Limb Ischemia</brief_title>
	<detailed_description>This protocol next clinical step biochemical assessment cell therapy approach treat Chronic Limb Threatening Ischemia ( CLI ) . Briefly , capability enlarge collateral artery ( `` arteriogenesis '' ) , stimulate growth new capillary , arteriole venule tissue level ( `` angiogenesis '' ) innate . Investigators attribute failure occur CLI ischemic environment . In first protocol investigator use external programmed pneumatic compression device ( Art-Assist Device ) improve hemodynamics limb importantly provide `` on-switch '' activate endothelium arteriogenesis begin . This new protocol provide second step improve environment ; improve cellular deficit protein signal . Investigators seek proteomic , biochemical , cytometry data need refine approach clinical trial perform . This project use FDA approve CMS reimburse product . Rationale Neovascularization CLI fail hemodynamic ( `` A '' ) cellular ( `` B '' ) reason : A ) The hemodynamic failure cause multi-level arterial occlusive disease lead : 1 . Attenuation infra-geniculate endothelial shear stress : Without stimulus , endothelial cell line small collateral artery induce attract capture circulate monocyte progenitor cell would orchestrate arteriogenesis . 2 . Impaired inflow oxygenate nutritive blood flow ischemic tissue 3 . Impaired clearance waste product metabolism ischemic tissue 4 . Impaired dissemination protein signal ischemic tissue would recruit pro-angiogenic reparative cell . 5 . Impaired arrival pro-angiogenic cell ischemic tissue . B ) Deficiency circulate progenitor cell population : These cell participate angiogenesis arteriogenesis . They deficient number function CLI patient . C ) Impaired immunity . Even blood flow improved population patient still succumb infection . Part relate poor wound management , impaired immunity . Our cell therapy approach design address . Specifically : A ) The hemodynamic failure cause multi-level arterial occlusive disease correct wear ACI device 1 . Restores endothelial shear stress need activate vascular endothelium start Arteriogenesis process . 2 . Increases delivery oxygenate nutritive blood flow ischemic tissue 3 . Clears waste product metabolism ischemic tissue 4 . Increases dissemination protein signal ischemic tissue would recruit pro-angiogenic reparative cell . 5 . Enhances delivery pro-angiogenic cell back ischemic tissue . B ) The deficiency circulate progenitor cell population correct : G-CSF ( Nuopogen , Amgen Inc. ) FDA approve progenitor/stem cell mobilization . It use clinically stand-alone neovascularization therapy . Investigators use protocol correct deficiency vital cell population CLI patient , enhance arteriogenesis angiogenesis . Investigators measure biochemical impact . C ) The Impaired immunity address G-CSF ( Nuopogen , Amgen Inc. ) FDA approve correct immunological deficit follow cytotoxic chemotherapy . CLI occur elderly , often diabetic , patient impaired immunity . Amputations result infection arise forefoot reach mid-foot . Our hypothesis : combine use PPCD G-CSF promote arteriogenesis . Investigators limit strong clinical evidence combine approach dramatically improve blood flow . The recently complete IRB project ( IRB # 12-1198 ) focus biochemistry PPCD . The present submission address biochemical impact PPCD G-CSF together . B.OBJECTIVES : Specific Aim 1 : measure influence progenitor cell mobilization PPCD proteomic profile investigator derive recently complete protocol ( IRB # 12-1198 ) . Ten CLI patient enrol . All wear PPCD . All receive 10 mcg/kg Filgrastim ( Nuopogen , Amgen Inc. ) total 5 dos . The FDA approve indication stem cell mobilization . The dosimetry less aggressive product label dosimetry spread every 72 hour rather day . The FDA grant PI IND waiver dose interval . As first protocol , cytometry yield distribution progenitor CD34+ VEGFR2+ cell monocyte ( CD14+ ) . The distribution mature circulate endothelial cell ( CD31+ ) cell measure reference point . As first protocol investigator proteomic survey measuring level cytokine associate arteriogenesis , well serum nitrite ( reflection nitric oxide synthase activity ) . Specific Aim 2 : investigator examine association biochemical data , hemodynamic testing , clinical course ( alleviation progression forefoot ischemic rest pain ischemic forefoot wound ) 6 month interval . Study Design : Ten CLI patient ischemic forefoot rest pain , non-healing forefoot ulceration , dry forefoot gangrene recruit . They already undergo standard care evaluation , include hemodynamic testing duplex ultrasound delineation arterial anatomy Non-invasive Vascular Laboratory . Those tibial artery occlusive disease , normal correct proximal aorto-ilio-femoral arterial anatomy , give option enrollment lieu surgery catheter revascularization . PPCD use continue present symptom resolve traditional revascularization becomes necessary achieve limb salvage . The three amendment first IRB submission ( IRB # 12-1198 ) : 1 . All receive 10 mcg/kg Filgrastim ( Nuopogen , Amgen Inc. ) total 5 dos . 2 . The 30 day CRC visit replace 14 day visit . 3 . Cytometry also perform 14 day visit . As first IRB submission , patient serve his/her control . Two `` pair '' blood specimen analyze per patient . A `` pair '' include phlebotomy prior immediately two hour PPCD . The first pair obtain enrollment CRC . The second pair do 2 week later 18-24 hour last dose G-CSF . The patient return standard care clinical evaluation , repeat hemodynamic test 6 month 14 day CRC evaluation . Baseline visit ( Vascular Surgery Clinic ) : 1 . Patients undergo standard care history physical ( H &amp; P ) examination . 2 . Other standard care test include : duplex ultrasound ( DUS ) , Ankle Toe Pressures . 3 . Upon verification patient eligible ( base inclusion/exclusion criterion ) , ICF ( Informed consent form ) , explain patient good explain study ask authorization participate . Day1 ( CRC ; Clinical Research Center , University Chicago ) : The following procedure do order : 1 . Initial blood draw ( 20 ml ) 2 . Each patient give Nuopogen shot ( 10 mcg/kg ) subcutaneously . 3 . Patients wear PPCD seat position ( 2-hour session ) . 4 . After 2-hour use PPCD , another blood draw do ( 20 ml ) . 5 . Patient give ample time fill quality life questionnaire study coordinator available time assist patient . 6 . Blood sample send Dr. T.C . HE , PhD Lab analysis . Days 4 , 7 , 10 , 13 ( Home clinic ) : The following procedure do : 1 . Nurse P.I . administer Nuopogen shot ( 10 mcg/kg ) subcutaneously , every 3rd day , total 5 Nuopogen shot . 2 . Patient continue use PPCD every day , least 3 hour day , till symptom resolve . Day14 ( CRC ; Clinical Research Center , University Chicago ) : The following procedure do order : 1 . Initial blood drawing ( 20 ml ) , 18-24 hour 5th shot Nuopogen . Blood sample send Dr. T.C . He , PhD Lab biochemical analysis . 2 . Patients wear PPCD 2 hour seat position . 3 . Just prior end 2-hour use PPCD , another blood draw do ( 20 ml ) . 4 . QOL fill patient . 5 . Patient return empty vial Nuopogen .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<criteria>1 . Male female age 40 85 . 2 . Chronic limb ischemia Fontaine Class III ( ischemic forefoot rest pain ) Class IV ( nonhealing ischemic ulcer , gangrene ) confirmatory noninvasive vascular testing . 1 . Acute limb ischemia require emergency treatment . 2 . Nonsalvageable foot ( e.g . extensive gangrene , advanced infection , rigor mortis , knee/hip flexion contracture , poststroke paralysis , hemiparesis ) . 3 . Untreated hypercoagulability disorder , sickle cell anemia , myeloproliferative disorder . 4 . Dialysis , sustain elevated Creatinine &gt; 4 mg/dl . 5 . Severe dementia ; bedridden ; noncompliance ; unlikely followup ; unreliable . 6 . Intolerance PPCD compression 7 . Morbid obesity ( Body Mass Index &gt; 34 ) 8 . Severe venous insufficiency cause venous stasis ulceration dermatitis . 9 . Uncorrected significant aortoiliac , common femoral , profunda femoral arterial disease 10 . Ulceration preclude PPCD placement . 11 . Active cancer . 12 . Allergy Nuopogen . 13 . Uncorrected symptomatic coronary artery disease 14 . History lymphoma leukemia</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Chronic low limb ischemia</keyword>
	<keyword>Art-Assist Device</keyword>
	<keyword>Neupogen</keyword>
</DOC>